Migraine
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patient Groups (EM / CM / MOH): 1. Age 18-55 years, any gender, Han ethnicity. 2. Meet the corresponding diagnostic criteria of the International Classification of Headache Disorders, 3rd edition (ICHD-3): (1) Episodic Migraine (EM): ICHD-3 code 1.1 or 1.2; (2) Chronic Migraine (CM): ICHD-3 code 1.3; (3) Medication-Overuse Headache (MOH): ICHD-3 code 8.2, with underlying headache type being migraine. 3. In the interictal period (no moderate-to-severe headache attack within 48 hours prior to blood sampling). 4. No initiation of new preventive medication in the past month, or have been on stable preventive treatment for at least one month. 5. No use of acute analgesic medication within the past 24 hours. 6. Capable of understanding the study procedures and providing written informed consent. Healthy Control Group (HC): 1. Age 18-55 years, matched to patient groups by gender and ethnicity (Han Chinese). 2. Generally healthy, with no history of headache (fewer than one headache episode per year) and no history of major physical or psychiatric disorders. 3. No recent acute illness (e.g., common cold, infection) within the past month. 4. No alcohol abuse; non-smoker or smoking < 5 cigarettes per day. 5. Body Mass Index (BMI) between 18.5 and 24.9 kg/m^2. 6. Provides written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with concomitant vertigo; 2. Patients diagnosed with other types of primary or secondary headache disorders (e.g., cluster headache, trigeminal neuralgia, intracranial mass lesions, cerebrovascular diseases, etc.); 3. Presence of severe organic diseases, including but not limited to: (1) Hepatic or renal dysfunction (ALT or AST > 2 x upper limit of normal [ULN]; serum creatinine > ULN); (2) Uncontrolled hypertension or diabetes mellitus (HbA1c > 7.0%); (3) Malignancy; (4) Autoimmune diseases; 4. History of psychiatric disorders (e.g., major depressive disorder, anxiety disorders, schizophrenia) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease); 5. Pregnancy or lactation; 6. Recent infection, fever, or significant psychological/physical stress within the past week; 7. History of alcohol abuse (alcohol intake > 280 g/week) or substance abuse (excluding acute analgesics contributing to MOH); 8. Participation in another clinical trial within the past month; 9. Brain MRI findings suggestive of secondary headache.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in metabolomic features; | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolite levels; | — |
Countries
China
Contacts
Public ContactLixue Chen
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed